Strong Revenue Growth:
Recent disclosures highlight year-over-year revenue increases in 2025 and further growth in early 2026, with guidance pointing to continued double-digit expansion. Record analysis volumes and scaling usage underpin this top-line momentum.
Customer Loyalty & Retention:
Net Dollar Retention improved and core genomics customers increased through 2025 into Q1 2026, indicating expanding spend and usage within the installed base. These trends suggest effective land-and-expand dynamics as newer applications drive deeper adoption.
Market Expansion:
The company is adding a record number of new customers and expanding in the U.S., including large health-system wins and broader adoption of MSK-ACCESS/MSK-IMPACT. Rising platform analyses across regions signal broader geographic traction.
